Heron Therapeutics, Inc., a biotech firm focused on developing treatments for unmet patient needs, has been making strides in the field with its proprietary Biochronomer drug delivery technology. This technology allows for the administration of short-acting pharmacological agents with a single dosage that lasts for days to weeks. Its product offerings include SUSTOL, an extended-release injection for the prevention of nausea and vomiting associated with chemotherapy, as well as CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist that also helps with chemotherapy-induced sickness. Additionally, Heron is developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. Its investigational agents, HTX-019 and HTX-034, target postoperative nausea and vomiting and postoperative pain management, respectively. With its headquarters in San Diego, California, Heron Therapeutics began as A.P. Pharma, Inc. in 1983 and rebranded as Heron Therapeutics, Inc. in January 2014.
Heron Therapeutics Inc's ticker is HRTX
The company's shares trade on the NASDAQ stock exchange
They are based in San Diego, California
There are 51-200 employees working at Heron Therapeutics Inc
It is herontx.com
Heron Therapeutics Inc is in the Healthcare sector
Heron Therapeutics Inc is in the Drug Manufacturers - Other industry
The following five companies are Heron Therapeutics Inc's industry peers: